Clinical data | |
---|---|
Trade names | Sibelium, others |
Other names | 1-[bis(4-fluorophenyl)methyl]-4-cinnamyl-piperazine |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | >99% |
Metabolism | Mainly CYP2D6 |
Metabolites | ≥15 |
Elimination half-life | 5–15 hrs (single dose) 18–19 days (multiple doses) |
Excretion | Feces, <1% urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.052.652 |
Chemical and physical data | |
Formula | C26H26F2N2 |
Molar mass | 404.505 g·mol−1 |
3D model (JSmol) | |
Melting point | 251.5 °C (484.7 °F) (dihydrochloride) |
| |
| |
(verify) |
Flunarizine, sold under the brand name Sibelium among others, is a drug classified as a calcium antagonist which is used for various indications.[1] It is not available by prescription in the United States or Japan. The drug was discovered at Janssen Pharmaceutica (R14950) in 1968.